- Home
- CRDF vs SGMT Comparison
CRDF vs SGMT Comparison
Compare CRDF & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- SGMT
- Stock Information
- Founded
- CRDF 1999
- SGMT 2006
- Country
- CRDF United States
- SGMT United States
- Employees
- CRDF N/A
- SGMT N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- SGMT
- Sector
- CRDF Health Care
- SGMT
- Exchange
- CRDF Nasdaq
- SGMT Nasdaq
- Market Cap
- CRDF 233.5M
- SGMT 269.2M
- IPO Year
- CRDF N/A
- SGMT 2023
- Fundamental
- Price
- CRDF $4.04
- SGMT $9.64
- Analyst Decision
- CRDF Strong Buy
- SGMT Strong Buy
- Analyst Count
- CRDF 6
- SGMT 5
- Target Price
- CRDF $11.92
- SGMT $26.60
- AVG Volume (30 Days)
- CRDF 1.4M
- SGMT 2.0M
- Earning Date
- CRDF 08-07-2025
- SGMT 08-13-2025
- Dividend Yield
- CRDF N/A
- SGMT N/A
- EPS Growth
- CRDF N/A
- SGMT N/A
- EPS
- CRDF N/A
- SGMT N/A
- Revenue
- CRDF $587,000.00
- SGMT N/A
- Revenue This Year
- CRDF N/A
- SGMT N/A
- Revenue Next Year
- CRDF N/A
- SGMT N/A
- P/E Ratio
- CRDF N/A
- SGMT N/A
- Revenue Growth
- CRDF N/A
- SGMT N/A
- 52 Week Low
- CRDF $2.01
- SGMT $1.73
- 52 Week High
- CRDF $5.64
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- CRDF 65.93
- SGMT 68.58
- Support Level
- CRDF $3.07
- SGMT $7.80
- Resistance Level
- CRDF $4.22
- SGMT $9.89
- Average True Range (ATR)
- CRDF 0.22
- SGMT 0.95
- MACD
- CRDF 0.08
- SGMT -0.01
- Stochastic Oscillator
- CRDF 87.35
- SGMT 76.43
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.